Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2025-03-12T05:28:29.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2025-03-05T00:36:08.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-25T19:13:27.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2025-02-18T13:50:44.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    2%
    Check dated 2025-02-11T10:04:12.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.9%
    Check dated 2025-02-04T05:37:20.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.